TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Piramal Pharma Limited
PPLPHARMA

Piramal Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 53/100 · Average See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹210.31

Change

+2.19 (1.05%)

Open

₹208.99

Prev. Close

₹208.12

Day High

₹212.4

Day Low

₹206.04

Volume Analysis

Traded

3,361,746

Delivered

1,381,410

Delivery %

41.09%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Low return on equity (-3.83%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹219.48 ₹215.94 ₹213.12 ₹209.58 ₹206.76 ₹203.22 ₹200.4
Fibonacci ₹215.94 ₹213.51 ₹212.01 ₹209.58 ₹207.15 ₹205.65 ₹203.22
Camarilla ₹212.06 ₹211.48 ₹210.89 ₹209.58 ₹209.73 ₹209.14 ₹208.56

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+23.8%

1 Week

-2.03%

1 Month

-3.83%

3 Months

+25.12%

6 Months

+47.58%

1 Year

+12.03%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-3.68%

Net margin -3.41% × asset turnover 0.5x × equity multiplier 2.16x

Company Overview

Sector

Healthcare

Market Cap

₹28,000 Cr

ROE

-3.83%

Book Value

₹61.4

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.

TopFund Analysis

Piramal Pharma Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Momentum (78/100), while Business Quality (30/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-3.83%). FII holding has been falling.

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

76

Growth

37

Valuation

50

Cash Flow

52

Corporate Governance

48

Momentum

78

Institutional Ownership

51

Business Quality

30

Risk & Volatility

60

Liquidity

71

From Screener.in

  • −Stock is trading at 3.42 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 7.03% over past five years.
  • −Company has a low return on equity of -0.88% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private Limited 18 Sep

Niche99 assigned Piramal Pharma an ESG rating of 67.1, Band: Leader.

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - FDA Inspection 14 Sep

US FDA inspected Morpeth, UK plant Sep 3-11, 2026, issuing Form-483 with 7 observations.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 Sep 08 Sep
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - ESG Rating 03 Sep

NSE Sustainability assigned Piramal Pharma an ESG rating of 65 for FY2025-26, up from 64.

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 Aug 26 Aug

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 1,749 1,911 1,959 2,552 1,951 2,242 2,204 2,754 1,934 2,044 2,140 2,752 2,270
Expenses + 1,617 1,646 1,690 2,022 1,747 1,900 1,866 2,193 1,827 1,885 1,944 2,291 2,075
Operating Profit 132 266 268 530 204 342 338 561 107 159 196 461 195
OPM % 8.0% 14.0% 14.0% 21.0% 10.0% 15.0% 15.0% 20.0% 6.0% 8.0% 9.0% 17.0% 9.0%
Other Income + 53 68 43 8 42 78 29 58 98 80 12 -116 109
Interest 119 110 106 114 107 108 103 104 86 82 89 83 88
Depreciation 174 185 186 196 185 192 197 243 197 203 213 218 224
Profit before tax -107 40 19 227 -45 120 67 273 -79 -46 -94 43 -7
Tax % -8.0% 87.0% 48.0% 55.0% 97.0% 81.0% 94.0% 44.0% 3.0% 115.0% 45.0% 121.0% 830.0%
Net Profit + -99 5 10 101 -89 23 4 154 -82 -99 -136 -9 -69
EPS in Rs -1 0 0 1 -1 0 0 1 -1 -1 -1 0 -1
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 6,315 6,559 7,082 8,171 9,151 8,869 9,205
Expenses + 4,887 5,609 6,453 6,974 7,706 7,947 8,195
Operating Profit 1,428 950 629 1,197 1,445 922 1,010
OPM % 23.0% 14.0% 9.0% 15.0% 16.0% 10.0% 11.0%
Other Income + 230 319 272 172 208 74 86
Interest 163 198 344 448 422 341 343
Depreciation 545 586 677 741 816 831 858
Profit before tax 949 485 -120 179 415 -176 -104
Tax % 12.0% 22.0% 55.0% 90.0% 78.0% 85.0% —
Net Profit + 835 376 -186 18 91 -326 -314
EPS in Rs — — -1 0 1 -2 -2
Dividend Payout % 0.0% 18.0% 0.0% 82.0% 20.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 4,610 5,511 5,580 6,588 6,801 6,835
Borrowings + 3,025 4,128 5,637 4,710 4,856 5,675
Other Liabilities + 2,047 1,781 1,893 2,461 2,447 3,770
Total Liabilities 10,677 12,605 14,303 15,083 15,429 17,607
Fixed Assets + 6,105 6,879 7,469 7,990 8,133 8,684
CWIP 627 1,172 1,419 1,116 977 1,100
Investments 123 267 639 385 291 437
Other Assets + 3,822 4,286 4,777 5,592 6,028 7,386
Total Assets 10,677 12,605 14,303 15,083 15,429 17,607
Equity Capital 995 1,186 1,193 1,323 1,324 1,327

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 598 766 484 1,005 892 1,653
Cash from Investing Activity + -4,464 -1,737 -1,334 -416 -488 -820
Cash from Financing Activity + 3,977 794 818 -422 -441 -39
Net Cash Flow 110 -177 -32 166 -37 794
CFO/OP 52 98 107 97 85 202
Free Cash Flow -5 -91 -461 294 233 776

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 35.02% → 34.8%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Others 0.38% 0.38% 0.37% 0.47% 0.45% 0.4% 0.34% 0.57% 0.51% 0.44% 0.34% 0.48%
Public 24.21% 22.41% 21.89% 20.2% 19.06% 18.85% 18.42% 19.46% 19.46% 19.35% 19.01% 37.62%
Promoters 35.02% 35.02% 35.02% 34.94% 34.94% 34.94% 34.94% 34.85% 34.85% 34.85% 34.85% 34.8%
FII 32.37% 32.51% 30.58% 31.41% 31.73% 31.68% 31.49% 30.86% 30.27% 29.66% 30.17% 12.51%
DII 8.01% 9.68% 12.12% 12.95% 13.8% 14.09% 14.78% 14.25% 14.89% 15.68% 15.61% 14.57%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Piramal Pharma Limited (this stock) 28,000 — 3.42 -3.83%
Neuland Lab Ltd. 28,085 56.4 14.98 21.2%
Rubicon Research Limited 27,748 96.3 21.46 27.0%
Acutaas Chemicals Limited 26,884 69.6 16.26 24.0%
Dr. Lal Path Labs Ltd. 32,299 57.4 12.83 22.3%
Granules India Limited 23,248 35.8 4.16 13.8%
Krishna Inst Of Med Sci L 32,765 157.0 13.88 11.3%

Which Mutual Funds Hold Piramal Pharma Limited?

Frequently Asked Questions about Piramal Pharma Limited

Community Sentiment

What are other investors saying about Piramal Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.